Ignite Creation Date:
2024-05-06 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 1:52 PM
Study NCT ID:
NCT04683770
Status:
UNKNOWN
Last Update Posted:
2020-12-24
First Post:
2020-12-19
Brief Title:
Prognostic Value of Biomarkers in HR HER2 - Advanced Breast Cancer
Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Organization:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study Overview
Official Title:
An Observational StudyPrognostic Value of Biomarkers in HR HER2 - Advanced Breast Cancer
Status:
UNKNOWN
Status Verified Date:
2020-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Our study is aimed to explore a prospective observational clinical study on the efficacy prediction and survival prediction of HR HER2 - biomarkers detection in patients with advanced breast cancer This study is a prospective observational clinical study We analyzed the incidence of biomarker mutations in HR HER2 - advanced breast cancer stage IV and the correlation between biomarkers and therapeutic efficacy survival and prognosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None